How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paritaprevir-ritonavir-ombitasvir-dasabuvir-ribavirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin (paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination. Area: Virology / H

marketed HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination HCV NS3/4A protease, NS5A protein, NS5B polymerase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin (paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin) — American Research Corporation. This combination inhibits hepatitis C virus (HCV) replication by blocking multiple viral enzymes essential for viral protein processing and RNA synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin TARGET	paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	American Research Corporation	marketed	HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
ABT450r-ABT267-ABT333 +/- Ribavirin	ABT450r-ABT267-ABT333 +/- Ribavirin	Ottawa Hospital Research Institute	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination class)

American Research Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin — Competitive Intelligence Brief. https://druglandscape.com/ci/paritaprevir-ritonavir-ombitasvir-dasabuvir-ribavirin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab